UTHR — United Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $10.95bn
- $8.65bn
- $2.33bn
- 98
- 66
- 82
- 96
Annual income statement for United Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1,449 | 1,483 | 1,686 | 1,936 | 2,328 |
| Cost of Revenue | |||||
| Gross Profit | 1,331 | 1,375 | 1,563 | 1,785 | 2,070 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 1,638 | 900 | 1,132 | 958 | 1,143 |
| Operating Profit | -190 | 583 | 554 | 978 | 1,185 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -165 | 639 | 594 | 951 | 1,274 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -105 | 515 | 476 | 727 | 985 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -105 | 515 | 476 | 727 | 985 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -105 | 515 | 476 | 727 | 985 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 16.4 | 11.7 | 12.8 | 15.2 | 19.9 |